Cascadian Therapeutics’ (CASC) Buy Rating Reaffirmed at Cowen and Company
Cascadian Therapeutics Inc. (NASDAQ:CASC)‘s stock had its “buy” rating reaffirmed by analysts at Cowen and Company in a research report issued to clients and investors on Monday.
Other analysts have also recently issued reports about the company. Cantor Fitzgerald restated a “hold” rating and set a $2.00 price target on shares of Cascadian Therapeutics in a report on Wednesday, June 15th. Zacks Investment Research cut Cascadian Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 15th. Finally, Jefferies Group restated a “buy” rating on shares of Cascadian Therapeutics in a report on Wednesday, June 15th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $3.20.
Cascadian Therapeutics (NASDAQ:CASC) traded down 2.01% on Monday, reaching $1.46. 773,280 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $1.32 and its 200 day moving average is $1.17. Cascadian Therapeutics has a 52 week low of $0.82 and a 52 week high of $3.75. The company’s market cap is $197.55 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/cascadian-therapeutics-casc-buy-rating-reaffirmed-at-cowen-and-company.html
Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.14. During the same period in the prior year, the company posted ($0.11) earnings per share. On average, equities analysts anticipate that Cascadian Therapeutics will post $5.02 earnings per share for the current year.
In other news, insider Scott Dunseth Myers bought 45,000 shares of the stock in a transaction dated Wednesday, August 17th. The shares were bought at an average cost of $1.15 per share, with a total value of $51,750.00. Following the completion of the transaction, the insider now directly owns 107,500 shares of the company’s stock, valued at $123,625. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 19.40% of the company’s stock.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.